NEW HAVEN, Conn.–(BUSINESS WIRE)–#ClinicalTrials—Trevi
Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company
focused on developing Nalbuphine®
ER for chronic pruritic conditions, today announced that Jennifer
Good, President and Chief Executive Officer, will present at the UBS
Global Healthcare Conference. The presentation will take place at the
Grand Hyatt in New York City on Monday, May 21 at 3:00 pm ET.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company
focused on developing Nalbuphine ER for chronic pruritic conditions.
Pruritus develops in various dermatologic, metabolic, hematologic and
neuropathic conditions. The Company is pursuing several pruritic
conditions for clinical development, including its lead indication of
prurigo nodularis. Prurigo nodularis is a chronic pruritic dermatologic
condition characterized by the presence of pruriginous lesions
(excoriative/ulcerative papules and nodules) on the skin. There are no
approved therapies in the US or EU for this condition.
Nalbuphine® ER is an oral extended release synthetic opioid
with a dual mechanism of action, mu receptor antagonist and kappa
receptor agonist, both of which have been shown in research to be
effective in abolishing itch. Because of Nalbuphine ER’s unique dual
mechanism of action, which has shown efficacy in addressing pruritus in
human clinical trials, the Company believes Nalbuphine ER can have broad
utility in treating chronic pruritus.
Founded in 2011, Trevi is headquartered in New Haven, CT. For additional
information, visit www.trevitherapeutics.com.
For Trevi Therapeutics, Inc.